Navigation Links
UC San Diego announces collaboration with Johnson & Johnson Pharmaceutical Research & Development
Date:11/20/2008

University of California, San Diego Health Sciences leaders have announced that they have executed a formal Memorandum of Understanding (MOU) with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), with the objective of developing future collaborations in biomedical research and education to advance human health.

The MOU establishes a framework for future research and training efforts between the UC San Diego School of Medicine, Skaggs School of Pharmacy and Pharmaceutical Sciences and the UC San Diego Medical Center health system, and J&JPRD, a pharmaceutical research and development company with expertise in small molecules, genomics, bioinformatics, high throughput screening, and structural biology.

"We are excited about this tremendous opportunity to partner with J&JPRD, which is a world leader in the development of new drugs. This collaboration will further accelerate our efforts at UC San Diego to translate the exciting discoveries being made every day in our laboratories into improved diagnostic and treatment technologies that benefit all patients," said David Brenner, M.D., UC San Diego Vice Chancellor for Health Sciences. "The ability to work more closely with colleagues in the private sector will strengthen our translational research program, and enhance the education of our medical, pharmacy and graduate students, in addition to boosting the potential for new product development."

Brenner joined with G. Diego Miralles, M.D., Head and Chief Medical Officer of J&JPRD's Research and Early Development unit based in San Diego, to sign the MOU in ceremonies at the UC San Diego School of Medicine.

Echoing Dr. Brenner's enthusiasm, Dr. Miralles noted that "academia and industry are natural partners since we have complimentary expertise and share the common goal of addressing unmet medical needs. Working closely with our neighbors at UCSD will help us find win-win opportunities and maximize our common capabilities. We are very excited about the potential of this partnership."

The two organizations plan to create education, training and research collaborations in biomedical science, medicine and public health, with a focus on projects that lead to new clinical applications. In addition to signing the MOU, the organizations also signed the first agreement between UC San Diego Health Sciences and J&JPRD under the MOU framework a contract for UC San Diego Professor of Pharmacology Larry Brunton, Ph.D., to conduct laboratory studies to evaluate the effects of new compounds on heart tissue.


'/>"/>

Contact: Leslie Franz
lfranz@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. InVitria to Launch "BE FREE" Promotion at TERMIS '08 in San Diego
2. Centennial Taking Control of Your Diabetes Conference Returns to San Diego to Bring Answers, Advocacy and Hope
3. Dr. Ron Greenspan has Been Selected for the 2008 Best of San Diego Award in the Orthodontists Category by the U.S. Local Business Association
4. Car Donations: "Tired Wheels" Turned Into Donation Dollars for Ronald McDonald House Charities, San Diego
5. UC San Diego to lead nationwide program in pharmacogenomics
6. Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego
7. Graves & Thyroid Disease National Patient Conference Set for San Diego, CA
8. Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008
9. Direct From Beijing, 2008 Olympic Gymnastic Superstars and Grammy Award Winning Icons Descend Upon San Diego to Tape ABC Network Womens Cancer Awareness Special, Frosted Pink With A Twist
10. San Diego Supercomputer Center director urges academia to make cyberinfrastructure real
11. CRH Medical Corporation opens Center in San Diego California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 28, 2017 , ... Semrock’s highly popular SearchLight Spectra Viewer ... resource for fluorescence microscopists and optical system designers, enabling The Right Solution, Right ... the globe, SearchLight has become a tremendously popular tool for the fluorescence imaging ...
(Date:4/27/2017)... ... April 27, 2017 , ... Thinksport, the leaders in safe, ... award-winning sunscreen they’ve used the same scientific approach to solving smelly, sweaty athletes, ... the aisles that contain harmful chemicals that should be put nowhere near your ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of its ... times purer and more potent than the market has seen before. Swissx uses proprietary ... well as a patented chromatography process for extraction, to produce its CBD oil--maximizing its ...
(Date:4/26/2017)... , ... April 26, 2017 , ... Journal of ... It can have severe consequences to overall dental health, including complications with speech, eating, ... turn to dental implants to replace lost teeth. As the number of tooth replacements ...
(Date:4/26/2017)... ... April 26, 2017 , ... The ... Excellence upon National Registry of Emergency Medical Technicians and welcomes this ... said Dr. Jan G. West, Ph.D. , CEO & Organizational Psychologist at ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... England , April 24, 2017 ... development, today announced the addition of a major ... ,Validated In-situ Plate Seeding,). The VIPS has been ... and 384 well microplates as part of the ... system offers a simple and more reliable solution ...
(Date:4/20/2017)... 2017 Research and Markets has ... and Market Prospects: Addressing Production Complexities Through Risk Management ... ... Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through ... assessment of the current trends in the global biosimilars ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: